Maintaining Market Dominance: Strong Buy Rating on Apellis Pharmaceuticals with a Target Price of $85

Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer from Needham reiterated a Buy rating on the stock and has a $85.00 price target.

Joseph Stringer has given his Buy rating due to a combination of factors including the strong performance and future sales potential of Apellis Pharmaceuticals’ product, Syfovre. Stringer’s analysis suggests that despite aggressive sales guidance from competitor Astellas, Apellis is well-positioned to maintain a dominant market share. His confidence is further bolstered by the company’s consistent sales estimates, which align closely with wider market expectations.
Furthermore, the anticipation of a favorable U.S. label update and the effect of a permanent J-code are seen as catalysts for significant growth. Stringer’s projection of continued market dominance by Apellis is underpinned by a robust sales estimate for the upcoming quarter, reinforcing his optimism. This leads to his reiteration of a Buy rating on Apellis Pharmaceuticals, complemented by a target price of $85, highlighting the strong investment potential he sees in the company.

In another report released on April 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $92.00 price target.

Based on the recent corporate insider activity of 121 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APLS in relation to earlier this year.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Apellis Pharmaceuticals (APLS) Company Description:

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.